Germline Multigene Panel Testing in Women With Invasive Lobular Cancer - Scorecard - MDSpire

Germline Multigene Panel Testing in Women With Invasive Lobular Cancer

  • By

  • Giovanni Corso

  • Elena Marino

  • Francesca Fava

  • Fabrizio Natali

  • Paolo Peterlongo

  • Matteo Dal Molin

  • Irene Feroce

  • Cristina Zanzottera

  • Giulia Massari

  • Susanna Di Silvestre

  • Micol Moscatiello

  • Andrea Franceschini

  • Vincenzo Bagnardi

  • Giuseppe Curigliano

  • Bernardo Bonanni

  • Paolo Veronesi

  • Francesco Bertolini

  • July 8, 2026

  • 0 min

Share

Clinical Scorecard: Genetic Multigene Panel Analysis in Women Diagnosed with Invasive Lobular Carcinoma

At a Glance

CategoryDetail
ConditionInvasive Lobular Carcinoma
Key MechanismsGermline pathogenic variants in genes such as CDH1 and BRCA2 are associated with increased risk.
Target PopulationWomen diagnosed with primary invasive lobular carcinoma.
Care SettingEuropean Institute of Oncology

Key Highlights

  • ILC accounts for 10% to 15% of all breast cancer cases.
  • Established risk factors include hormone replacement therapy and family history of breast cancer.
  • Germline PVs in CDH1 and BRCA2 confer high risk for ILC.
  • The study evaluates outcomes of germline PVs in a large cohort of ILC patients.
  • Polygenic risk scores may serve as prognostic markers in ILC.

Guideline-Based Recommendations

Diagnosis

  • Confirm diagnosis of primary ILC through histopathologic evaluation.

Management

  • Consider genetic counseling and multigene panel testing for women diagnosed with ILC.

Monitoring & Follow-up

  • Systematic recording of clinical, histopathologic, personal, and family history data.

Risks

  • Monitor for the presence of germline pathogenic variants associated with breast cancer risk.

Patient & Prescribing Data

Women diagnosed with invasive lobular carcinoma, particularly those diagnosed before age 40.

Emerging targeted treatments may be relevant for patients with BRCA-mutated tumors.

Clinical Best Practices

  • Utilize genetic testing to inform tailored surveillance strategies.
  • Implement psychological counseling for patients undergoing genetic testing.

Related Resources & Content

Original Source(s)

Germline Multigene Panel Testing in Women With Invasive Lobular Cancer

  • by Giovanni Corso, Elena Marino, Francesca Fava, Fabrizio Natali, Paolo Peterlongo, Matteo Dal Molin, Irene Feroce, Cristina Zanzottera, Giulia Massari, Susanna Di Silvestre, Micol Moscatiello, Andrea Franceschini, Vincenzo Bagnardi, Giuseppe Curigliano, Bernardo Bonanni, Paolo Veronesi, Francesco Bertolini

  • July 8, 2026

Related Content

ASCO26: Jennifer Ligibel, MD, BWEL

Dana-Farber Cancer Institute's Dr. Jennifer Ligibel shared updated results from the BWEL study showing a weight loss intervention led to significantly better physical function, global physical and mental health, and symptom in patients with early breast cancer.

  • July 1, 2026

  • 1 min
Breast Cancer Incidence in Asian American, Native Hawaiian, and Pacific Islander Populations, 2000-2022

Editorial: Advancement of chemotherapy in breast cancer: predictive markers, resistance mechanism and therapeutic strategies